Health · Pharma & Biotech · 23 hrs ago
Strand plans overseas expansion for blood-based cancer screening test
Strand Life Sciences plans to expand CancerSpot overseas, targeting the US, Southeast Asia and West Asia.
The blood-based test looks for DNA patterns that may be linked to cancer, using genome sequencing, DNA analysis and artificial intelligence.
The company is seeking US FDA approval, and expects a key step in that process around February or March next year; it says the US would be its next export market after approval.
CancerSpot is a screening test, not a diagnosis, so a positive result needs further tests such as imaging, endoscopy or a biopsy.
In a study across 43 Indian hospitals, it detected 72 per cent of cancers, including around 65 to 70 per cent at early stages, and had a 1.4 per cent false-positive rate in an independent group.
Strand says the test is meant to complement established screening, including mammography and colonoscopy, and may cover cancers with limited routine screening options.
Strand aims to reduce the India price below ₹10,000 over the next few years; it currently costs up to ₹25,000, and the company has not given a timeline for any further price reduction.
Strand Life Sciences plans to expand its CancerSpot blood-based cancer screening test into the US, Southeast Asia and West Asia.
The company is pursuing US Food and Drug Administration approval and expects a key regulatory milestone around February-March next year.
CancerSpot uses genome sequencing, DNA methylation analysis and artificial intelligence to identify patterns in blood DNA fragments that may be associated with cancer.
The test is a screening tool, not a definitive diagnosis, and a positive result requires follow-up investigations.
Strand aims to lower the test’s price in India from up to ₹25,000 to less than ₹10,000 over the next few years.
- Who
- Strand Life Sciences, a subsidiary of Reliance Industries, is seeking to expand the test. CEO Dr Ramesh Hariharan described the company’s global ambition.
- What
- Strand plans to take CancerSpot, a blood-based cancer screening test, into overseas markets.
- When
- The company expects a key milestone in the US FDA regulatory process around February-March next year.
- Where
- The company is targeting the US, Southeast Asia and West Asia, among other regions.
- Why
- Strand says there is good opportunity in these markets and that regulatory clearances can build confidence among clinicians and other stakeholders.
This story does not have two clearly opposing sides.
Strand conducted a study across 43 hospitals in India involving around 1,400 participants.
Strand expects a key milestone in its US FDA approval process.
- Overseas targets
- US, Southeast Asia and West Asia
- India price
- Up to ₹25,000 currently; Strand targets less than ₹10,000 over the next few years
- Study
- Four years across 43 hospitals in India
- Study participants
- Around 1,400, including about 950 people with cancer and 450 healthy individuals
- False-positive rate
- 1.4 per cent in an independent set of participants
What people are saying
In most regions of the world, one doesn't need it (regulatory approval to operate). Our aspiration is global. There is good opportunity in Southeast Asia, West Asia and other parts of the world, which we will be aggressively pursuing,